CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
Potential Benefits
- Sustained growth hormone elevation with less frequent dosing
- May support improvements in lean body mass
- Research suggests potential benefits for fat metabolism
- May support recovery and tissue repair processes
- Convenience of less frequent injections compared to non-DAC version
Recommended Starting Dose
1-2 mg subcutaneously per week
Based on published research protocols. Not a prescription.
Dosing Protocol
Typically injected once or twice per week due to the extended half-life. Common doses range from 1-2 mg per injection. Cycles of 8-12 weeks are common, followed by a 4-6 week break.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Effects on sleep and subjective well-being may appear within 1-2 weeks. Body composition changes typically require 8-16 weeks.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Prolonged GH elevation may cause water retention and joint stiffness
- Potential for elevated cortisol and prolactin
- Headache and flushing
- Numbness or tingling
- Non-physiologic sustained GH release (does not mimic natural pulsatile pattern)
- May affect insulin sensitivity with prolonged use
More in Growth Hormone
CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone in a pulsatile fashion, mimicking the body's natural rhythm. It is often paired with a GHRP like Ipamorelin for synergistic effects.
Ipamorelin
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is considered one of the milder GH secretagogues, producing a targeted GH pulse without significant increases in cortisol, prolactin, or appetite. It is frequently combined with CJC-1295 (no DAC).
Sermorelin
Sermorelin Acetate
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the naturally occurring 44-amino-acid GHRH molecule. It was previously FDA-approved for diagnosing and treating growth hormone deficiency in children. It stimulates the pituitary to produce and release GH in a natural, pulsatile manner.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.